Kolfarma was born in 2009, from research carried out at the University of Genoa on the anti-epileptic effect of a whey protein, Alpha-Lactalbumin (ALAC) .

Results obtained from clinical studies on patients with epilepsy, treated with antidepressant drugs serotonin reuptake inhibitors (SSRIs) lead to the search for a new way to increase the synthesis of serotonin in the central nervous system (CNS). For this action, ALAC is identified.

Subsequent studies have highlighted the role of the intestinal microbiota in the morbidity of various pathologies.

In particular, Kolfarma is committed to promoting projects to understand how the modulation of the microbiota can influence the functioning of other organs, with a primary interest in the brain and the Central Nervous System.

Kolfarma is constantly committed to the dissemination of new scientific knowledge , also through sponsorship of activities such as conferences, congresses, workshops, webinars and educational campaigns.

Kolfarma is proud to continue funding preclinical and clinical studies to better understand the role of the microbiota in the control of epileptic seizures and in the management of various neuropsychiatric disorders and their comorbidities, particularly in the pediatric area.

Kolfarma owns 3 international patents , demonstrating the quality and seriousness of the research carried out and the products marketed, in Italy and also internationally.